Dendritic cell-based vaccines for the therapy of experimental tumors.
Dendritic cells (DCs) are believed to be the most potent antigen-presenting cells able to link the innate and adaptive immune systems. Many studies have focused on different immunotherapeutic approaches to applying DCs as tools to improve anticancer therapy. Although a number of investigations suggesting the benefit of DC-based vaccination during anticancer therapy have been reported, the general knowledge regarding the ultimate methods of DC-vaccine preparation is still unsatisfactory. In this article, the perspectives of DC-based anti-tumor immunotherapy and optimizing strategies of DC vaccination in humans in light of results obtained in mouse models are discussed.
Pajtasz-Piasecka
Elzbieta
E
Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland. pajtasz@iitd.pan.wroc.pl
Indrová
Marie
M
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002454:Cell Differentiation; D002478:Cells, Cultured / Q000276:immunology / Q000637:transplantation; D003131:Combined Modality Therapy; D016207:Cytokines / Q000235:genetics; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000637:transplantation; D004354:Drug Screening Assays, Antitumor; D005544:Forecasting; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000627:therapeutic use; D016233:Immunotherapy, Active; D007271:Injections, Intradermal; D007272:Injections, Intralymphatic; D007279:Injections, Subcutaneous; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D009928:Organ Specificity; D014611:Vaccination
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines